Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia-Reference-Cited by-同舟云学术

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

Published:2017-03-08 Issue:7 Volume:143 Page:1311-1318
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Hoffmann Verena S.,Hasford Joerg,Deininger Michael,Cortes Jorge,Baccarani Michele,Hehlmann Rüdiger

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-017-2385-7/fulltext.html

Reference33 articles.

1. Baccarani M et al (2009) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113:4497–4504. doi: 10.1182/blood-2008-12-191254

2. Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884. doi: 10.1182/blood-2013-05-501569

3. Cortes JE et al (2009) High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 27:4754–4759. doi: 10.1200/JCO.2008.20.3869

4. Cortes JE et al (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424–430. doi: 10.1200/JCO.2009.25.3724

5. Cortes JE et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486–3492. doi: 10.1200/JCO.2011.38.7522

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Brief View on the Role of Enzymes in the Diagnosis, Monitoring and Treatment of Diseases and their Application in Medical, Genetics and Proteomics Laboratory Methods;Journal of Ardabil University of Medical Sciences;2024-04-01

2. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

3. From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure;Pharmaceutics;2023-03-28

4. Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy;Gene;2022-03

5. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions;Blood Reviews;2021-09